HAP International and LaSal Laboratories Announce Lab Results Showing Chelated Silver Kills Cancer Cells
HAP International (http://www.hapsilver.com) and LaSal Laboratories (http://www.silversoftforskin.com/) today announced the results of their recent laboratory tests that successfully used chelated silver to treat breast cancer in mice and skin cancer In Vitro.
Bloomfield, CT (PRWEB) January 11, 2011
HAP International (http://www.hapsilver.com) and LaSal Laboratories (http://www.silversoftforskin.com/) today announced the results of their recent laboratory tests that successfully used chelated silver to treat breast cancer in mice and skin cancer In Vitro. The tests began in 2009 and concluded in 2010. The test results support the conclusion that a strong bonded chelate can destroy cancer cells.
Specifically, the final results of the In Vivo study proved that the LaSal Laboratories patented 840ppm chelated silver solution was effective in inhibiting the growth of the MDA-MB-231 human mammary tumor, producing a growth delay value of >4.3 days. The final results also showed that in the In Vitro study, a concentration of 6 PPM silver complex resulted in 100% death of TE 354.T basal skin cancer cells. Building on these promising results, the next phase will continue to measure efficacy and toxicity of lesser PPM of LaSal silver until a satisfactory complex is developed. Southern Research Institute (http://www.southernresearch.org) in Birmingham, Ala. conducted the tests using two chelated silvers, but only the patented chelated silver complex from LaSal Laboratories, of Provo, Utah, was effective in killing cancer cells In Vivo. Thus, the next phase will use the LaSal Laboratories chelate.
In designing the tests, Leonard Paul felt that a strong bonded chelate would not fall victim to the NaCl in the blood, so efficacy would not disappear. Paul also felt that the positively charged silver would be attracted to the negatively charged tumor cells. According to Paul, that is exactly what happened.
According to Michael Roberts, Ph.D. and Senior Project leader for Southern Research Institute, “It has long been known that proliferating cells readily uptake positively charged drugs. Hence, a rapidly dividing cancer cell would be expected to uptake positively charged silver ions more readily than normal cells. Once inside the cells, silver ions would be expected to interact with the cellular DNA causing cell death. Silver has been known to be non-toxic for many years. Our studies would suggest that we could deliver silver ions to cancer cells at concentrations high enough to kill the cancer, without causing toxicity to surrounding normal cells. This should be especially true if direct intra-tumoral delivery is used.”
Southern Research Institute also concluded that the in vitro study results indicate that a topical formulation could be attempted to carry the silver complex through the skin barrier with a concentration of as little as 6PPM in the tumor, with tumor regression resulting. If such a study were successful, according to Roberts, HAP International could have a likely drug candidate for topical application to AKs, a known common pre-cancerous lesion that develops on aging, especially sun damaged skin. Depending on the results of toxicity testing, the treatment could also prove successful on benign tumors such as warts.
About HAP International:
HAP International is dedicated to testing and ultimately using a patented chelated silver to treat breast, skin and a variety of other cancers. HAP was founded in honor of the late Dr. Howard A. Paul, son of Leonard Paul, inventor of the HAP patents. For further information visit: (http://www.hapsilver.com).
About LaSal Laboratories:
Based in Provo, Utah, LaSal Laboratories is focused on human and animal health. LaSal’s principal consumer product is Silver Soft(R) For Skin. Patent Applications are pending or secured on selected methodologies and technologies in Canada, China, The European Union, and the United States of America. For further information visit: (http://www.silversoftforskin.com/).
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/01/prweb4959504.htm